Niagen Bioscience Shifts Focus to Pharmaceuticals with Rare Disease Drug Candidate
Event summary
- Niagen Bioscience reported Q2 2026 revenue of $29.8M, with Tru Niagen® contributing $24.2M.
- Launched Niagen Plus telehealth platform and received LegitScript certification for at-home injection kits.
- Introduced NB4168, a rare disease drug candidate targeting Ataxia-Telangiectasia (A-T), receiving FDA Rare Pediatric Disease designation and EMA Orphan Medicinal Product Designation.
- Engaged Evotec as contract research organization for preclinical studies on NB4168, set to begin in Q3 2026.
The big picture
Niagen Bioscience is expanding beyond nutritional supplements into pharmaceuticals, leveraging its expertise in NAD+ science. The strategic shift comes as the company reports steady revenue growth and invests heavily in research and development. Success will depend on balancing short-term profitability with long-term drug development timelines.
What we're watching
- Pharma Transition
- Whether Niagen can successfully pivot from supplements to pharmaceuticals while maintaining profitability.
- Regulatory Momentum
- The pace at which NB4168 advances through clinical trials and secures additional regulatory designations.
- Market Competition
- How Niagen competes with other NAD+ boosters like NMN in the supplement market while investing in its pharmaceutical pipeline.